13G Filing: Nexthera Capital and Catalyst Biosciences Inc. (CBIO)

Page 6 of 9 – SEC Filing

Item 1(a).
Name of Issuer:
Catalyst Biosciences, Inc. (the “Issuer”).
Item 1(b).
Address of Issuer’s Principal Executive Offices:
260 Littlefield Avenue
South San Francisco, California 94080
Item 2(a).
Name of Persons Filing:
This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):
i)
Nexthera Capital LP (“Nexthera Capital”);
ii)
Nexthera Capital GP LLC (“Nexthera GP”);
iii)
Daniel Malek (“Mr. Malek”); and
iv)
Ori Hershkovitz (Mr. Hershkovitz”).
Nexthera GP is the general partner of Nexthera Capital. Mr. Malek and Mr. Hershkovitz are the managing members Nexthera GP By virtue of these relationships, each of Nexthera GP, Mr. Malek and Mr. Hershkovitz may be deemed to have voting and dispositive power with respect to the shares of Common Stock (as defined below) beneficially owned by Nexthera Capital.
Item 2(b).
Address of Principal Business Office or, if None, Residence:
The address of the principal business office of each of the Reporting Persons is 900 Third Avenue, Suite 201.1, New York, New York 10022.
Item 2(c).
Citizenship:
i)
Nexthera Capital is a Delaware limited partnership;
ii)
Nexthera GP is a Delaware limited liability company;
iii)
Mr. Malek is a citizen of Belgium; and
iv)
Mr. Hershkovitz is a citizen of Israel.
Item 2(d).
Title of Class of Securities:
Common Stock, par value $0.001 per share (the “Common Stock”)
Item 2(e).
CUSIP Number:
14888D208

Follow Gyre Therapeutics Inc. (NASDAQ:GYRE)